| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, ... Journal of clinical oncology 27 (22), 3584, 2009 | 2749 | 2009 |
| A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. A Passaniti, RM Taylor, R Pili, Y Guo, PV Long, JA Haney, RR Pauly, ... Laboratory investigation; a journal of technical methods and pathology 67 (4 …, 1992 | 1031 | 1992 |
| Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth H Zhang, DZ Qian, YS Tan, KA Lee, P Gao, YR Ren, S Rey, H Hammers, ... Proceedings of the National Academy of Sciences 105 (50), 19579-19586, 2008 | 712 | 2008 |
| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, ... The Lancet 387 (10032), 2008-2016, 2016 | 651 | 2016 |
| Consensus guidelines for the use and interpretation of angiogenesis assays P Nowak-Sliwinska, K Alitalo, E Allen, A Anisimov, AC Aplin, R Auerbach, ... Angiogenesis 21, 425-532, 2018 | 552 | 2018 |
| Kidney cancer RJ Motzer, N Agarwal, C Beard, GB Bolger, B Boston, MA Carducci, ... Journal of the National Comprehensive Cancer Network 7 (6), 618-630, 2009 | 425 | 2009 |
| Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α DZ Qian, SK Kachhap, SJ Collis, HMW Verheul, MA Carducci, P Atadja, ... Cancer research 66 (17), 8814-8821, 2006 | 373 | 2006 |
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ... Clinical Cancer Research 17 (23), 7337-7346, 2011 | 347 | 2011 |
| Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma A Orillion, A Hashimoto, N Damayanti, L Shen, R Adelaiye-Ogala, S Arisa, ... Clinical cancer research 23 (17), 5187-5201, 2017 | 333 | 2017 |
| Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589 DZ Qian, Y Kato, S Shabbeer, Y Wei, HMW Verheul, B Salumbides, ... Clinical Cancer Research 12 (2), 634-642, 2006 | 320 | 2006 |
| Targeting tumor angiogenesis with histone deacetylase inhibitors L Ellis, H Hammers, R Pili Cancer letters 280 (2), 145-153, 2009 | 292 | 2009 |
| The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor … DZ Qian, X Wang, SK Kachhap, Y Kato, Y Wei, L Zhang, P Atadja, R Pili Cancer research 64 (18), 6626-6634, 2004 | 279 | 2004 |
| The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth R Pili, J Chang, RA Partis, RA Mueller, FJ Chrest, A Passaniti Cancer research 55 (13), 2920-2926, 1995 | 279 | 1995 |
| Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1 OV Volpert, R Pili, HA Sikder, T Nelius, T Zaichuk, C Morris, CB Shiflett, ... Cancer cell 2 (6), 473-483, 2002 | 269 | 2002 |
| VEGF165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo J Mühlhauser, MJ Merrill, R Pili, H Maeda, M Bacic, B Bewig, A Passaniti, ... Circulation research 77 (6), 1077-1086, 1995 | 265 | 1995 |
| Kidney cancer, version 3.2015 RJ Motzer, E Jonasch, N Agarwal, C Beard, S Bhayani, GB Bolger, ... Journal of the National Comprehensive Cancer Network 13 (2), 151-159, 2015 | 258 | 2015 |
| The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for … D Keizman, M Ish-Shalom, P Huang, MA Eisenberger, R Pili, H Hammers, ... European Journal of Cancer 48 (2), 202-208, 2012 | 255 | 2012 |
| Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone … JE Karp, I Gojo, R Pili, CD Gocke, J Greer, C Guo, D Qian, L Morris, ... Clinical Cancer Research 10 (11), 3577-3585, 2004 | 253 | 2004 |
| Ageing and COVID-19: What is the role for elderly people? DR Petretto, R Pili Geriatrics 5 (2), 25, 2020 | 237 | 2020 |
| Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer R Pili, M Häggman, WM Stadler, JR Gingrich, VJ Assikis, A Björk, ... Journal of Clinical Oncology 29 (30), 4022-4028, 2011 | 230 | 2011 |
